Breakthrough in cancer treatment. New drugs effectively target KRAS mutation

This mutation occurs in about 25% of all malignant tumors, especially common in pancreatic, lung, and colorectal cancer.

For many years, KRAS was considered "untouchable" — creating a drug against it was impossible. Now the situation has changed. New drugs have learned to either switch the mutant protein to an inactive state or completely destroy it inside the cell.

The most notable results have been achieved with the KRAS G12C mutation. In clinical trials, tumors significantly shrank in some patients, and long-term disease stabilization was achieved in others.

The new drugs act more selectively than standard chemotherapy and offer hope for better treatment of the most aggressive forms of cancer. The third phase of trials is currently underway.

Source: Cancer Cell, March 9, 2026 DOI: 10.1016/j.ccell.2026.01.001 "Emerging landscape of KRAS inhibitors in cancer treatment"